Key result
Paricalcitol treatment of As4.1 cells suppressed renin expression through a transcriptional regulatory complex including CREB1, NCOR1, and VDR binding to the CRE-like domain in the renin enhancer region.
Paricalcitol suppresses renin expression in As4.1 cells via a transcriptional regulatory complex involving VDR, CREB1, and NCOR1.
Answers are grounded in this paper and cite their sources.
Does not support clinical renin modulation yet; extends cell-based VDR mechanisms but leaves open in vivo translation.
BACKGROUND: The vitamin D receptor (VDR) is involved in the regulation of renin expression and vitamin D analogs down-regulated renin mRNA expression in As4.1 cells. METHODS: Microarray analysis was used to assess the VDR-mediated gene expression profile in As4.1 cells treated with paricalcitol, followed by real-time RT-PCR. Mechanistic analyses were done using siRNA, electrophoretic mobility shift assay (EMSA) and Western blotting. RESULTS: Microarray analysis shows that 709 target genes were affected by paricalcitol with 286 up- and 423 downregulated. A number of major pathways were impacted including transcription factors. Real-time RT-PCR confirmed the microarray results. Treatment of the cells with siRNA against nuclear receptor co-repressor (NCOR1) eliminated VDR-mediated renin suppression. Using EMSA, paricalcitol treatment reduced the level of protein complex binding to the cyclic AMP-responsive element (CRE)-like domain in the renin distal enhancer region. VDR, CRE-binding protein (CREB1) and NCOR1 were identified in the complex binding to the CRE-like domain by Western blot in the paricalcitol-treated cells. Paricalcitol treatment resulted in an increase in the VDR level, but no significant change in the CREB1 and NCOR1 levels. CONCLUSION: These results suggest that VDR-mediated renin suppression likely acts through a transcriptional regulatory complex including CREB1, NCOR1 and VDR that binds to the CRE-like domain in the renin enhancer region.
No takes yet. Share an insight, caveat, or question.
Nakane et al. (2007) studied this question. Paricalcitol was evaluated on VDR-mediated gene expression profile and renin suppression mechanisms. Paricalcitol treatment of As4.1 cells suppressed renin expression through a transcriptional regulatory complex including CREB1, NCOR1, and VDR binding to the CRE-like domain in the renin enhancer region.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: